Pharmacologic agents for tobacco dependence treatment: 2011 update

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.

Original languageEnglish (US)
Pages (from-to)85-92
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Tobacco Use Disorder
Tobacco Use
Tobacco
Drug Therapy
Cardiovascular Diseases
Mortality
Pandemics
Therapeutics
Smoke
Lung Diseases
Cause of Death
Lung Neoplasms
Chronic Disease
Public Health
Smoking
Health
Research
Neoplasms

Keywords

  • Cardiovascular disease
  • Pharmacotherapy
  • Tobacco dependence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{85b312afc0454fc9ad6748ea35132aa5,
title = "Pharmacologic agents for tobacco dependence treatment: 2011 update",
abstract = "Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.",
keywords = "Cardiovascular disease, Pharmacotherapy, Tobacco dependence",
author = "Hays, {James Taylor} and McFadden, {David D} and Ebbert, {Jon Owen}",
year = "2012",
month = "2",
doi = "10.1007/s11883-011-0211-2",
language = "English (US)",
volume = "14",
pages = "85--92",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Pharmacologic agents for tobacco dependence treatment

T2 - 2011 update

AU - Hays, James Taylor

AU - McFadden, David D

AU - Ebbert, Jon Owen

PY - 2012/2

Y1 - 2012/2

N2 - Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.

AB - Tobacco use remains the most important worldwide cause of preventable death due mainly to cancer, cardiovascular disease, and chronic lung disease. If the current tobacco pandemic continues for another 20 years, the annual global tobacco-attributable mortality will exceed 8 million. In the US and many European countries, public health and tobacco control efforts combined with effective tobacco dependence treatment using combined behavioral treatment and pharmacotherapy have contributed significantly to steadily declining rates of tobacco use. Subsequent declines in cardiovascular disease and lung cancer death rates are directly attributable to these lower rates of tobacco use. Despite smoking bans, health warnings and effective pharmacotherapy, one in five Americans continue to smoke. Continued research in tobacco dependence treatment has resulted in newer and more effective pharmacotherapy. In this review, we provide a current update of pharmacologic agents for tobacco dependence treatment and a discussion of recent controversy regarding adverse effects of some these medications.

KW - Cardiovascular disease

KW - Pharmacotherapy

KW - Tobacco dependence

UR - http://www.scopus.com/inward/record.url?scp=84857631364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857631364&partnerID=8YFLogxK

U2 - 10.1007/s11883-011-0211-2

DO - 10.1007/s11883-011-0211-2

M3 - Article

C2 - 22002681

AN - SCOPUS:84857631364

VL - 14

SP - 85

EP - 92

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 1

ER -